Using CRISPR-Cas systems as antimicrobials. (June 2017)

• Record Type: Journal Article
• Authors: Bikard, David; Barrangou, Rodolphe
• Is Part Of: Current opinion in microbiology. Volume 37(2017)
• Page Start: 155
• Page End: 160
• Publication Date: 2017-06
• Subjects: Microbiology -- Periodicals; 579.05
• DOI: 10.1016/j.mib.2017.08.005
• Languages: English
• ISSNs: 1369-5274

Abstract

Highlights: Self-targeting by CRISPR-Cas systems is typically lethal in bacteria. CRISPR-Cas systems can be repurposed to drive programmed bacterial death. CRISPR arrays and Cas nucleases can be delivered to target organisms using phages. There is a need to engineer delivery vectors to enable CRISPR-based antimicrobials. Abstract : Although CRISPR-Cas systems naturally evolved to provide adaptive immunity in bacteria and archaea, Cas nucleases can be co-opted to target chromosomal sequences rather than invasive genetic elements. Although genome editing is the primary outcome of self-targeting using CRISPR-based technologies in eukaryotes, self-targeting by CRISPR is typically lethal in bacteria. Here, we discuss how DNA damage introduced by Cas nucleases in bacteria can efficiently and specifically lead to plasmid curing or drive cell death. Specifically, we discuss how various CRISPR-Cas systems can be engineered and delivered using phages or phagemids as vectors. These principles establish CRISPR-Cas systems as potent and programmable antimicrobials, and open new avenues for the development of CRISPR-based tools for selective removal of bacterial pathogens and precise microbiome composition alteration.